Description
Retatrutide is a clinical-stage synthetic peptide engineered to activate three metabolic receptors at once: GIP, GLP-1 and glucagon. This “triple agonist” design is the current frontier of incretin research.
Published phase-2 clinical data and preclinical models focus on body-composition change, energy expenditure and hepatic fat, with the glucagon component studied specifically for its contribution to energy output. It remains investigational and unapproved, making it one of the most closely watched molecules in metabolic research.
Format & handling
Supplied as a lyophilized powder in a sealed, batch-stamped vial. Store sealed at −20 °C protected from light. For laboratory work, reconstitute with bacteriostatic water shortly before use and refrigerate any working solution at 2–8 °C.
For laboratory research use only — not for human or veterinary use. The summary above describes published research for scientific context and makes no claims about this product.
